Biomarker counseling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey

Kristian S Frederiksen, Thomas R Nielsen, Ildebrando Appollonio, Birgitte Bo Andersen, Mario Riverol, Mercè Boada, Mathieu Ceccaldi, Bruno Dubois, Sebastiaan Engelborghs, Lutz Frölich, Lucrezia Hausner, Audrey Gabelle, Tomasz Gabryelewicz, Timo Grimmer, Bernard Hanseeuw, Jakub Hort, Jacques Hugon, Vesna Jelic, Anne Koivisto, Milica G KrambergerThibaud Lebouvier, Alberto Lleó, Alexandre de Mendonça, Flavio Nobili, Pierre-Jean Ousset, Robert Perneczky, Marcel Olde Rikkert, David Robinson, Olivier Rouaud, Elisabet Sánchez, Isabel Santana, Nikolaos Scarmeas, Katerina Sheardova, Stephanie Sloan, Luiza Spiru, Elka Stefanova, Latchezar Traykov, Görsev Yener, Gunhild Waldemar

Onderzoeksoutput: Article

1 Citaat (Scopus)

Samenvatting

OBJECTIVES: Mild cognitive impairment (MCI) is associated with an increased risk of further cognitive decline, partly depending on demographics and biomarker status. The aim of the present study was to survey the clinical practices of physicians in terms of biomarker counseling, management, and follow-up in European expert centers diagnosing patients with MCI.

METHODS: An online email survey was distributed to physicians affiliated with European Alzheimer's disease Consortium centers (Northern Europe: 10 centers; Eastern and Central Europe: 9 centers; and Southern Europe: 15 centers) with questions on attitudes toward biomarkers and biomarker counseling in MCI and dementia. This included postbiomarker counseling and the process of diagnostic disclosure of MCI, as well as treatment and follow-up in MCI.

RESULTS: The response rate for the survey was 80.9% (34 of 42 centers) across 20 countries. A large majority of physicians had access to biomarkers and found them useful. Pre- and postbiomarker counseling varied across centers, as did practices for referral to support groups and advice on preventive strategies. Less than half reported discussing driving and advance care planning with patients with MCI.

CONCLUSIONS: The variability in clinical practices across centers calls for better biomarker counseling and better training to improve communication skills. Future initiatives should address the importance of communicating preventive strategies and advance planning.

Originele taal-2English
Pagina's (van-tot)324-333
Aantal pagina's10
TijdschriftInternational Journal of Geriatric Psychiatry
Volume36
Nummer van het tijdschrift2
Vroegere onlinedatum7 sep 2020
DOI's
StatusPublished - feb 2021

Bibliografische nota

© 2020 John Wiley & Sons Ltd.

Vingerafdruk

Duik in de onderzoeksthema's van 'Biomarker counseling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey'. Samen vormen ze een unieke vingerafdruk.

Citeer dit